Clinical trial · Interventional
Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts
The Efficacy of Intralesional Measles, Mumps, Rubella (MMR) Vaccine, Intralesional Candidal Antigen and Topical Podophyllin in Treatment of Genital Warts: A Comparative Study
NCT03853785CI-TRIAL-00037558unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study compares the safety and efficacy of intralesional Candidal antigen versus Intralesional MMR vaccine versus podophyllin for treatment of genital warts.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Condylomata Acuminata | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Candida antigen | Biological | — | UNRESOLVED |
| MMR vaccine | Biological | — | UNRESOLVED |
| Topical Podophyllin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Intralesional MMR vaccine
- description
- Intralesional Mumps, measles and rubella (MMR) vaccine in genital warts
- interventionNames
- Biological: MMR vaccine
- type
- ACTIVE_COMPARATOR
- label
- intralesional candida antigen
- description
- intralesional candida antigen in genital warts
- interventionNames
- Biological: Candida antigen
- type
- ACTIVE_COMPARATOR
- label
- Topical Podophyllin
- description
- Topical Podophyllin in genital warts
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with anogenital warts with ages ranging from 3 to 50 years * Genital warts resistant to treatment * Genital warts that had relapsed at least once after treatment with any of the tissue-destructive modalities. Exclusion Criteria: * Patients with any evidence of immunosuppression * Eczematous skin disorder * Those with any history of hypersensitivity to Candida albicans antigen * Pregnant or lactating women.
References
Publications (0)
Data not yet available
No reference posted for this study.